Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Gastrointestinal Stromal Tumors 3Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Pathologic Complete Response 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neoplasms 1Melanoma 1Hemangiosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 11Nivolumab 4Erlotinib Hydrochloride 3Docetaxel 3Cetuximab 3Capecitabine 3tislelizumab 2spartalizumab 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Gemcitabine 2Filgrastim 2Cyclophosphamide 2tremelimumab 1sargramostim 1ribociclib 1poly ICLC 1pexidartinib 1mirabegron 1futibatinib 1etoposide phosphate 1entinostat 1durvalumab 1ciforadenant 1cemiplimab 1capivasertib 1bempegaldesleukin 1avelumab 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × pexidartinib × Sarcoma × Clear all
NCT02452424 2020-03-05

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

Daiichi Sankyo

Phase 1/2 Terminated
78 enrolled 19 charts
DermatologicGastrointestinalGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Ovarian Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡